Preclinical study demonstrates strong neutralizing antibody responses against the Delta variant using an Alhydroxiquim-II-adjuvanted spike vaccine, suggesting a scalable COVID-19 platform.
, including Delta. The strong humoral and Th1-biased immunogenicity of CoVac-II is driven by use of Alhydroxiquim-II (AHQ-II), the first adjuvant in an authorized vaccine that acts through the dual Toll-like receptor (TLR)7 and TLR8 pathways, as part of the Covaxin vaccine. Our data suggest AHQ-II/spike protein combinations could constitute safe, affordable, and mass-manufacturable COVID-19 vaccines for global distribution.
No takes yet. Share an insight, caveat, or question.
Counoupas et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: